PL2512470T3 - Oszczędzające ppar tiazolidynodiony i połączenia do leczenia chorób neurodegeneracyjnych - Google Patents
Oszczędzające ppar tiazolidynodiony i połączenia do leczenia chorób neurodegeneracyjnychInfo
- Publication number
- PL2512470T3 PL2512470T3 PL10798884T PL10798884T PL2512470T3 PL 2512470 T3 PL2512470 T3 PL 2512470T3 PL 10798884 T PL10798884 T PL 10798884T PL 10798884 T PL10798884 T PL 10798884T PL 2512470 T3 PL2512470 T3 PL 2512470T3
- Authority
- PL
- Poland
- Prior art keywords
- ppar
- combinations
- treatment
- neurodegenerative diseases
- thiazolidinediones
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28671309P | 2009-12-15 | 2009-12-15 | |
| US28676509P | 2009-12-15 | 2009-12-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2512470T3 true PL2512470T3 (pl) | 2017-06-30 |
Family
ID=43589788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10798884T PL2512470T3 (pl) | 2009-12-15 | 2010-12-15 | Oszczędzające ppar tiazolidynodiony i połączenia do leczenia chorób neurodegeneracyjnych |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20130053350A1 (pl) |
| EP (2) | EP2512470B1 (pl) |
| JP (1) | JP2013514368A (pl) |
| KR (1) | KR20120103711A (pl) |
| CN (1) | CN102791269A (pl) |
| AU (1) | AU2010331926B2 (pl) |
| CA (1) | CA2783556C (pl) |
| DK (1) | DK2512470T3 (pl) |
| ES (1) | ES2617704T3 (pl) |
| HU (1) | HUE033199T2 (pl) |
| MX (1) | MX2012006730A (pl) |
| NZ (1) | NZ600421A (pl) |
| PL (1) | PL2512470T3 (pl) |
| RU (1) | RU2570424C2 (pl) |
| WO (1) | WO2011075514A1 (pl) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8912335B2 (en) | 2009-12-15 | 2014-12-16 | Metabolic Solutions Development Company, Llc | PPAR-sparing thiazolidinedione salts for the treatment of metabolic diseases |
| WO2011133226A2 (en) | 2010-04-22 | 2011-10-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method for enhancing learning and memory impaired by neurodegenerative disorders and compounds and compositions for effecting the same |
| US9907767B2 (en) | 2010-08-03 | 2018-03-06 | Velicept Therapeutics, Inc. | Pharmaceutical compositions and the treatment of overactive bladder |
| US9504679B2 (en) | 2011-12-19 | 2016-11-29 | Bjoern Colin Kahrs | Pharmaceutical compositions comprising glitazones and Nrf2 activators |
| US20130158077A1 (en) | 2011-12-19 | 2013-06-20 | Ares Trading S.A. | Pharmaceutical compositions |
| MX2014015310A (es) * | 2012-06-15 | 2015-07-06 | Found Biomedical Res & Innov | Agente profilactico y/o terapeutico para el deterioro cognoscitivo leve. |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| US20160051529A1 (en) * | 2012-12-11 | 2016-02-25 | Metabolic Solutions Development Company Llc | Ppar-sparing thiazolidinediones and combinations for the treatment of neurodegenerative and other metabolic diseases |
| HUE035803T2 (en) | 2012-12-21 | 2018-05-28 | Sanofi Sa | Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists |
| MX2016000724A (es) | 2013-07-22 | 2016-04-13 | Metabolic Solutions Dev Co Llc | Compuestos de reserva de los receptores activados del proliferador de peroxisoma (ppar) para el tratamiento de enfermedades metabolicas. |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| WO2015126915A2 (en) | 2014-02-18 | 2015-08-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method of improving cognition and social behavior in humans having deficits therein due to neurological disorders and compounds and compositions therefor |
| NZ725492A (en) * | 2014-04-02 | 2023-06-30 | Minoryx Therapeutics S L | 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| CN108290824B (zh) | 2015-10-23 | 2022-03-11 | B3Ar治疗股份有限公司 | 索拉贝隆两性离子及其应用 |
| EP3749292A1 (en) | 2018-02-08 | 2020-12-16 | ENYO Pharma | Use of modulators of neet proteins for the treatment of infection |
| US20210251923A1 (en) * | 2018-06-14 | 2021-08-19 | Curasen Therapeutics, Inc. | Methods for improving neurological diseases and disorders |
| CN111803502A (zh) * | 2020-06-30 | 2020-10-23 | 安域生物制药(杭州)有限公司 | 去甲乌药碱预防及治疗阿尔茨海默病的应用 |
| CN112587664A (zh) * | 2020-12-29 | 2021-04-02 | 四川大学华西医院 | 长链脂酰辅酶a合成酶4的抑制剂在治疗帕金森疾病中的应用 |
| CN115531368A (zh) * | 2021-06-14 | 2022-12-30 | 谭文 | R-氨基甲酸酯-β-苯乙醇胺类化合物治疗学习和记忆缺陷以及神经退行性疾病的应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| TW438587B (en) * | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| GB0023971D0 (en) * | 2000-09-29 | 2000-11-15 | Smithkline Beecham Plc | Novel pharmaceutical |
| US20060089387A1 (en) * | 2004-10-26 | 2006-04-27 | Le Huang | Stabilized pharmaceutical composition comprising antidiabetic agent |
| EP2902026B1 (en) * | 2006-03-16 | 2017-10-04 | Metabolic Solutions Development Company LLC | Thiazolidinedione analogues for the treatment of metabolic inflammation mediated disease |
| CA2646170A1 (en) * | 2006-03-16 | 2007-09-27 | Metabolic Solutions Development Company | Combination therapies of thiazolidinedione analogues and glucocorticoid agonists |
| CN101454006B (zh) * | 2006-03-16 | 2012-12-26 | 新陈代谢解决方案开发公司 | 用于治疗高血压以及用于降低血脂的噻唑烷二酮类似物 |
| CN101848901B (zh) * | 2007-09-14 | 2012-11-21 | 新陈代谢解决方案开发公司 | 用于治疗高血压的噻唑烷二酮类似物 |
| WO2010105048A1 (en) * | 2009-03-12 | 2010-09-16 | Metabolic Solutions Development Company | Thiazolidinedione analogues |
-
2010
- 2010-12-15 EP EP10798884.2A patent/EP2512470B1/en active Active
- 2010-12-15 ES ES10798884.2T patent/ES2617704T3/es active Active
- 2010-12-15 CA CA2783556A patent/CA2783556C/en active Active
- 2010-12-15 CN CN2010800638949A patent/CN102791269A/zh active Pending
- 2010-12-15 RU RU2012129931/04A patent/RU2570424C2/ru active
- 2010-12-15 PL PL10798884T patent/PL2512470T3/pl unknown
- 2010-12-15 WO PCT/US2010/060449 patent/WO2011075514A1/en not_active Ceased
- 2010-12-15 DK DK10798884.2T patent/DK2512470T3/en active
- 2010-12-15 HU HUE10798884A patent/HUE033199T2/en unknown
- 2010-12-15 JP JP2012544743A patent/JP2013514368A/ja active Pending
- 2010-12-15 MX MX2012006730A patent/MX2012006730A/es active IP Right Grant
- 2010-12-15 KR KR1020127018390A patent/KR20120103711A/ko not_active Ceased
- 2010-12-15 EP EP16197227.8A patent/EP3202401B1/en not_active Not-in-force
- 2010-12-15 NZ NZ600421A patent/NZ600421A/en not_active IP Right Cessation
- 2010-12-15 AU AU2010331926A patent/AU2010331926B2/en not_active Ceased
- 2010-12-15 US US13/515,522 patent/US20130053350A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| NZ600421A (en) | 2014-06-27 |
| KR20120103711A (ko) | 2012-09-19 |
| EP2512470B1 (en) | 2016-11-30 |
| EP2512470A1 (en) | 2012-10-24 |
| HUE033199T2 (en) | 2017-11-28 |
| JP2013514368A (ja) | 2013-04-25 |
| RU2012129931A (ru) | 2014-01-27 |
| RU2570424C2 (ru) | 2015-12-10 |
| EP3202401B1 (en) | 2019-10-23 |
| AU2010331926B2 (en) | 2014-03-27 |
| US20130053350A1 (en) | 2013-02-28 |
| CA2783556A1 (en) | 2011-06-23 |
| AU2010331926A1 (en) | 2012-06-21 |
| DK2512470T3 (en) | 2017-02-27 |
| WO2011075514A1 (en) | 2011-06-23 |
| MX2012006730A (es) | 2012-07-30 |
| CA2783556C (en) | 2017-12-12 |
| ES2617704T3 (es) | 2017-06-19 |
| CN102791269A (zh) | 2012-11-21 |
| EP3202401A1 (en) | 2017-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201202596B (en) | Compounds for the treatment of dyslipidemia and related diseases | |
| GB0910003D0 (en) | Novel compounds for the treatment of neurodegenerative diseases | |
| ZA200906210B (en) | 3-Imidazolyl-Indoles for the treatment of proliferative diseases | |
| EP2621499A4 (en) | METHODS OF TREATING ALLERGIC DISEASES | |
| IL216509A0 (en) | Use of an anti-tau ps422 antibody for the treatment of brain diseases | |
| EP2318005A4 (en) | NEUROPROTECTIVE AGENTS FOR THE PREVENTION AND TREATMENT OF NEURODEEGENERATIVE DISEASES | |
| IL239368A0 (en) | Sparing–ppar thiazolidinediones and combinations for the treatment of neurodegenerative diseases of the nervous system | |
| GB201021103D0 (en) | New compounds for the treatment of neurodegenerative diseases | |
| EP2004204A4 (en) | TREATMENT OF NEURODEGENERATIVE DISEASES | |
| SG173672A1 (en) | Novel ortho-aminoamides for the treatment of cancer | |
| GB0906159D0 (en) | Drug combination for the treatment of proteostatic diseases | |
| ZA201201287B (en) | Therapeutic aryl-amido-aryl compounds and their use | |
| IL214349A0 (en) | Compositions and methods for the treatment of cancer | |
| IL215940A0 (en) | Clavulanate formulation for neuroprotection and treatment of neurodegenerative disorders | |
| IL241253A0 (en) | Peptides for the treatment of neurodegenerative diseases | |
| ZA201208389B (en) | Treatment of proliferative diseases | |
| IL215990A0 (en) | Phosphotetrahydfropyran compounds for the treatment of wounds and fibrotic disorders | |
| ZA201305970B (en) | Arylosulfonami for the treatment of cns diseases | |
| GB0809476D0 (en) | Treatment of neurodegenerative disorders | |
| GB0610183D0 (en) | Treatment of neurodegenerative diseases | |
| PL2442811T3 (pl) | Teobromina w terapii kaszlu | |
| IL225624A0 (en) | Treatment with porphyrin in neurodegenerative diseases | |
| ZA201005770B (en) | The treatment of damaged skin | |
| HK1170238A (en) | Indolyl-substituted pyrazino-quinolines and their use for the treatment of cancer | |
| GB0716577D0 (en) | Treatment and prevention of neurodegenerative diseases |